TheraRadar
← Back
Data updated: Jul 17, 2026

Dr. Reddy's

Generics
OncologyCardiovascularInfectious Disease Execution: Excellent

Dr. Reddy's is a generic drug manufacturer focused on Oncology, Cardiovascular, Infectious Disease. Key products include PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE.

1974
Since
314
Drugs
-
Trials
5
New Drugs (2yr)
Modality:
7 Small Molecules

Dr. Reddy's at a Glance

  • Strong track record with 96% execution quality across 99 trials
  • Fast trial execution (2 months median completion)

Dr. Reddy's's Key Drugs

Dr. Reddy's's core commercial portfolio centers on DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, EZETIMIBE AND SIMVASTATIN, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Oncology

Breast Cancer

DNA Approved 2013
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Pain

Cough

Approved 2025
EZETIMIBE AND SIMVASTATIN
Metabolic

Atherosclerotic Vascular Disease

NPC1L1 Approved 2017
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
Immunology

Osteoarthritis

COX-1 Approved 2020
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE
Metabolic

Obesity

Approved 2024

Dr. Reddy's's Recent FDA Approvals

Dr. Reddy's secured 5 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.
BENDAMUSTINE HYDROCHLORIDE NDA
2025-07-03
bendamustine hydrochloride
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE NDA
2025-05-30
phenylephrine hydrochloride
Cough
DAPTOMYCIN NDA
2024-11-21
daptomycin
Skin and Skin Structure Infections
BORTEZOMIB NDA
2024-08-26
bortezomib

Dr. Reddy's's Therapeutic Areas

Dr. Reddy's's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular, across 0 biologic and 7 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 32%
24 drugs Phase 3: 1 Phase 1: 1
Cardiovascular 21%
16 drugs
Infectious Disease 18%
13 drugs Phase 2: 1 Phase 1: 1
Neurology 15%
9 drugs Phase 3: 2 Phase 2: 2 Phase 1: 1
Respiratory 14%
11 drugs

Dr. Reddy's's Top Competitors

Dr. Reddy's's closest competitors by therapeutic-area and drug-target overlap include Merck, GE HEALTHCARE, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Merck big-pharma
Oncology, Infectious Disease, Cardiovascular, Respiratory
GE HEALTHCARE specialty
Neurology, Cardiovascular, Infectious Disease, Oncology, Respiratory
Pfizer big-pharma
Oncology, Infectious Disease, Neurology
Novartis big-pharma
Oncology, Cardiovascular, Respiratory
Baxter specialty
Infectious Disease, Cardiovascular, Oncology

Dr. Reddy's Pipeline Snapshot

Dr. Reddy's has 9 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 3 Phase 2 and 3 Phase 1.

3
Phase 3
3
Phase 2
3
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 10/11 completed
  • • Speed: 2 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges